Financial Performance Overview
Rossari Biotech Limited reported strong financial results for FY 2025-26 with consolidated revenue growing 15.2% to ₹23,963.65 million from ₹20,802.94 million in FY25. Net profit increased 9.4% to ₹1,492.13 million, with basic earnings per share at ₹26.95. Export contribution remained significant at 26% of total turnover, showing 11% year-on-year growth. Standalone performance was even stronger with revenue growth of 22% to ₹17,520.66 million and profit after tax of ₹1,428.38 million.
Operational Highlights and Capacity Expansion
The company executed substantial capacity expansion with total capital expenditure of ₹2,445 million in FY26. Key projects included commissioning additional 20,000 MTPA capacity at Dahej I and a new 30,000 MTPA ethoxylation facility at Dahej II, bringing total ethoxylation capacity to 66,000 MTPA. Total installed capacity reached 387,100 MTPA across 8 manufacturing hubs. The company also established global presence through new subsidiaries in Saudi Arabia, Singapore, UAE, and Thailand, expanding operations to over 80 countries.
Sustainability and ESG Performance
Rossari Biotech demonstrated strong commitment to sustainability with comprehensive ESG disclosures. The company achieved 33% renewable energy usage, reduced Scope 1 emissions by 37.25%, and maintained zero liquid discharge at its Silvassa facility. Employee welfare metrics showed 100% coverage for provident fund and gratuity for both employees and workers, with zero safety incidents reported across all operations. The company spent ₹40.46 million on CSR initiatives focused on healthcare, education, and livelihood support.
Corporate Actions and Governance
The Board recommended a final dividend of ₹0.50 per equity share (25% on face value of ₹2 each) with record date set for July 10, 2026. The 17th Annual General Meeting is scheduled for July 20, 2026 via video conference. Corporate governance remained robust with a board composition of 6 directors (2 executive, 4 independent including 2 women independent directors) and comprehensive committee structures. The company maintained strong compliance with SEBI regulations and Companies Act requirements.
Financial Position and Cash Flows
Total assets increased to ₹17,636.36 million (standalone) with property, plant and equipment net carrying amount of ₹4,665.03 million (consolidated). Cash flow from operations was ₹650.68 million, while investing activities used ₹2,194.81 million primarily for capacity expansion. Financing activities generated ₹1,863.22 million through increased borrowings. Working capital loans rose significantly to ₹2,837.14 million from ₹754.52 million in FY25.
Subsidiary Performance and Related Party Transactions
Material subsidiaries showed mixed performance: Unitop Chemicals generated revenue of ₹9,222.68 million with PAT of ₹373.34 million, Tristar Intermediates reported PAT of ₹114.53 million, while Buzil Rossari recorded a loss of ₹127.11 million. The company approved material related party transactions with Unitop Chemicals for FY26-27 with aggregate value of ₹10,290 million covering goods purchase, sales, and infrastructure sharing.
Research and Innovation
The company invested ₹184.31 million in research and development, launching the Rossari Global Research & Innovation Centre (GRIC) in Navi Mumbai. Over 70 new products were developed across personal care, agro, and technical textiles segments, including innovations in biosurfactants (sophorolipids), BIOPULSE bio-based pretreatment, and flow chemistry processes.
Regulatory Compliance and Audit
Financial statements received unmodified audit opinion from Walker Chandiok & Co LLP, with one key audit matter identified around revenue recognition involving judgment about timing and transaction price. The company maintained compliance with SEBI listing regulations, Indian Accounting Standards (Ind AS), and all statutory requirements including audit trail preservation at application level.